Whitepaper

Small Molecule APIs: Aligning Drug Strategy with Partnering Strategy

Small Molecule APIs: Aligning Drug Strategy with Partnering Strategy

Getting drugs to market faster and more economically is prompting new drug product development strategies to support better business and patient outcomes. Development of critical drug substances, particularly novel small molecule active pharmaceutical ingredients (APIs), is now being turned over to outsourced partners who have become the integral, primary drivers of the product’s overall development and go-to-market strategy.